Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alemtuzumab, Rituximab and GM-CSF for High Risk CLL
NCT00562328Phase 2Completed
- Sponsor
- Mayo Clinic
- Start
- Jan 2008
- Primary completion
- Feb 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of alemtuzumab, rituximab and sargramostim in chronic lymphocytic leukemia (CLL), sponsored by Mayo Clinic. Primary endpoints: Number of Confirmed Responses (Complete or Partial Response) at 6 months and Toxicity Assessment. Started Jan 2008; status: completed.
02
Drugs
alemtuzumabrituximabsargramostim
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00562328.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00562328.